P38 Mitogen-activated Protein Kinases is Required for Counteraction of 2-Methoxyestradiol to Estradiol-Stimulated Cell Proliferation and Induction of Apoptosis in Ovarian Carcinoma Cells Via Phosphorylation Bcl-2

S. Z. Bu,Q. Huang,Y. M. Jiang,H. B. Min,Y. Hou,Z. Y. Guo,J. F. Wei,J. W. Wang,X. Ni,S. S. Zheng
DOI: https://doi.org/10.1007/s10495-006-4064-z
2006-01-01
APOPTOSIS
Abstract:INTRODUCTION:2-Methoxyestradiol (2ME2), a natural endogenous product of estradiol (E2) metabolism, has been shown to be a selective apoptotic agent for cancer cells but not for normal cells. In this study, we determined that 2ME2 counteracts E2-stimulated cell growth and induces apoptosis in ovarian carcinoma cells. In addition, we demonstrate that 2ME2 induces apoptosis via p38 and phospho-Bcl2 pathway.METHODS:2ME2 and/or E2 were administered to the OVCAR-3 (human ovarian cancer) cell line. Cell growth inhibition was analyzed by [3H] Thymidine incorporation assay and DNA fluorometric assay. Cell apoptosis was tested by DNA fragmentation analysis and FACS. The signaling pathway was determined by a series of biochemical assays.RESULTS:2ME2 inhibited estradiol-stimulated cell growth and induced apoptosis in an ovarian carcinoma cell line. MAPK and p38, but not JNK, were found to be critical mediators in this process. Expression of a dominant negative mutant of p38 kinase or p38 specific inhibitor, SB 203580, almost completely blocked the process. Furthermore, Bcl-2 phosphorylation was required for 2ME2-induced effects.CONCLUSION:Our data suggest that 2ME2 inhibits E2-stimulated proliferation and induces apoptosis in ovarian carcinoma cells. Furthermore, activation of p38 and phosphorylation of Bcl-2 plays a critical role in the mechanism. 2ME2 therefore, may have a clinical application for the treatment of ovarian cancer.
What problem does this paper attempt to address?